LINTEX
920106
LINGOOD
833284
NTGEC
870436
CG MED EQUIP.
838810
Jiayu Holding
300117
CN Stock MarketDetailed Quotes
300878 Zhejiang Wecome Pharmaceutical
- 14.37
- -0.60-4.01%
Market Closed Feb 28 15:00 CST
2.08BMarket Cap-62.48P/E (TTM)
15.03High14.36Low22.04KlotVolume14.94Open14.97Pre Close32.27MTurnover1.53%Turnover RatioLossP/E (Static)144.79MShares23.7852wk High1.54P/B2.07BFloat Cap13.3152wk Low17.96Limit Up144.12MShs Float59.90Historical High11.98Limit Down4.48%Amplitude13.31Historical Low0.25Dividend TTM14.64Avg Price12.41KlotAsk1.74%Div YieldTTM100Lot Size8.79KlotBid
Zhejiang Wecome Pharmaceutical News
Express News | Zhejiang Wecome Pharmaceutical: The product Xuesaitong dispersible tablets has been selected for the national Chinese Patent Medicine procurement alliance centralized bulk procurement.
6 popular stocks with 4 limit-ups in 6 days: A wholly-owned subsidiary plans to invest in the construction of a "new project" | Selected post-market announcements.
In 6 days, 4 hot stocks in the Robot Concept, the subsidiary plans to invest in the construction of a "new project," a leading financial IT company worth billions will change ownership, and the "number one" in PC security products is expected to have a Net income loss in the 2024 fiscal year...
Weikang Pharmaceutical: 2024 Annual Results Forecast
On December 31, A-share investment warning: Zhejiang Wecome Pharmaceutical and its actual controller Liu Zhongliang are being investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws.
Guo Yongfang, a shareholder of China Investment Technology, plans to reduce his shareholding by no more than 1%; Xiao Jinming, a shareholder of YingTong Telecommunication, intends to decrease his shareholding by no more than 2.47%; Mingchun Technology, a shareholder of Jingsheng Co., plans to reduce its stake by no more than 2%; Anyuan Coal Industry Group has not yet obtained the "Free Transfer Agreement" signed with Jiangneng Group and Jiangte Holdings; Zhongbai Holdings Group has not yet received the specific implementation plan from Wuhan Business Alliance; Zhejiang Wecome Pharmaceutical and its actual controller Liu Zhongliang are under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure regulations.
A-share volatility | The actual controller was put under investigation, Zhejiang Wecome Pharmaceutical dropped over 12%, hitting a new low in nearly three months.
Gelonghui, December 30 | Zhejiang Wecome Pharmaceutical (300878.SZ) experienced a drop of over 12% during the trading session, currently priced at 15.59 yuan, reaching a new low in nearly three months, with a total market value of 2.254 billion yuan. According to reports, the company and its actual controller Liu Zhongliang received the "Notice of Case Filing" issued by the China Securities Regulatory Commission on December 27, 2024, for suspected violations of information disclosure laws and regulations. The China Securities Regulatory Commission has decided to file a case against the company and Liu Zhongliang. As of the end of the third quarter, Liu Zhongliang Hold 60.89% of the shares of Zhejiang Wecome Pharmaceutical, making him the largest Shareholder of the company and its actual controller. It is reported that since 2024, Zhejiang Wecome Pharmaceutical has encountered multiple...
Express News | Zhejiang Wecome Pharmaceutical responded to being investigated: there are issues with the actual controller's fund usage.
Breaking! This company and its actual controller have been investigated by the CSRC for suspected violations of information disclosure laws and regulations | Post-market announcement highlights.
Sufa Technology Industry: plans to acquire 71.965% equity of China Nuclear West Instruments, which is expected to constitute a significant asset restructuring.
Express News | Zhejiang Wecome Pharmaceutical: The company and its actual controller Liu Zhongliang received the "Notice of Case Filing" from the China Securities Regulatory Commission.
Zhejiang Wecome Pharmaceutical (300878.SZ): Pharmaceutical production license change.
On November 13, GeLongHui reported that zhejiang wecome pharmaceutical (300878.SZ) announced the recent acquisition of the "Pharmaceutical Production License" issued by the Zhejiang Provincial Drug Administration, agreeing to the application for change of the "Pharmaceutical Production License". This change mainly involves changes in the enterprise's responsible person.
A-share traditional Chinese medicine stocks surged, with zhejiang wecome pharmaceutical and many other stocks hitting the limit up.
Gelonghui on November 12: Zhejiang Wecome Pharmaceutical, Wanbangde Pharmaceutical Holding Group, Shaanxi Kanghui Pharmaceutical all hit the daily limit up, TeYi Pharmaceutical Group, China Resources Sanjiu Medical & Pharmaceutical, Xiangxue Pharmaceutical followed the upward trend.
Weikang Pharmaceutical: Report for the third quarter of 2024
Zhejiang Wecome Pharmaceutical (300878.SZ) released its performance for the first three quarters, with a net income of 44.1 million yuan, a year-on-year decrease of 36.41%.
zhejiang wecome pharmaceutical (300878.SZ) disclosed its third quarter report for 2024, achieving revenue of 3....
Wecome Pharmaceutical Amends Drug Production License
Weikang Pharmaceutical: 2024 Semi-Annual Report
Weikang Pharmaceutical: 2024 Semi-Annual Report Summary
Zhejiang Wecome Pharmaceutical (300878.SZ) announced its performance for the first half of the year, with a net income of 14.1921 million yuan, a decrease of 78.04%.
Zhejiang Wecome Pharmaceutical (300878.SZ) released its 2024 interim report, with a revenue of 0.297 billion...
Express News | Zhejiang Wecome Pharmaceutical: net income of 14.1921 million yuan in the first half of the year, a year-on-year decrease of 78.04%.
Express News | Zhejiang Wecome Pharmaceutical: Net income in the first half of 2024 decreased by 78.04% year-on-year.
Zhejiang Wecome Pharmaceutical (300878.SZ): Currently, there is no drug available to treat monkeypox.
Zhejiang Wecome Pharmaceutical (300878.SZ) stated on the investor interaction platform on August 21 that the company currently has no drugs for treating monkeypox.
Traditional Chinese medicine stocks in A-shares continue to strengthen, xiangxue pharmaceutical has two consecutive boards.
On August 1, Gelunhui reported that Xiangxue Pharmaceutical has risen for two consecutive days, while Wecome Pharmaceutical increased by over 10%. Guangdong Jiangxi Wannianqing Cement, Zhejiang Xinguang Pharmaceutical, Mayinglong Pharmaceutical Group, China Resources Sanjiu Medical & Pharmaceutical followed the trend.
